Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 66Carcinoma, Non-Small-Cell Lung 39Breast Neoplasms 32Triple Negative Breast Neoplasms 25Neoplasm Metastasis 18Neoplasms 15Lung Neoplasms 15Colorectal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Stomach Neoplasms 6Ovarian Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Head and Neck Neoplasms 5Gallbladder Neoplasms 5Fallopian Tube Neoplasms 5Adenocarcinoma 5Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Pancreatic Ductal 4Carcinoma 4Neoplasms by Site 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Brain Neoplasms 3Biliary Tract Neoplasms 3Vaccinia 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

Paclitaxel 8Hyperthermic Intraperitoneal Chemotherapy 6Mitomycin 5Cisplatin 5Fluorouracil 4Bevacizumab 4Oxaliplatin 3Leucovorin 3Doxorubicin 3Cytoreduction Surgical Procedures 3Carboplatin 3Blood Specimen Collection 3sodium thiosulfate 2pembrolizumab 2Standard of Care 2Laparoscopy 2strattice 1soluble LAG-3 protein, human 1relacorilant 1oregovomab 1olaparib 1nilotinib 1liposomal doxorubicin 1irinotecan sucrosofate 1dehydroftorafur 1avelumab 1X-Rays 1Topotecan 1Taxes 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × 130-nm albumin-bound paclitaxel × 1 year × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡